Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Opioid Pain Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCN9A (Nav1.7) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCN9A HEK293 Membrane Fraction – Theoretical MW ~226 kDa. Sequence Verified. Endotoxin Controlled. Preserves native glycosylation and TTX binding site folding. | View SCN9A Products |
| Gene Delivery | SCN9A Lentivirus Premade Particles – Full-length ORF, High Titer (>10⁸ TU/mL), Sequence Verified. For stable Nav1.7+ cell lines with native multi-pass transmembrane conformation. | View SCN9A Products |
| Benchmark Ab | Anti-SCN9A (Extracellular Loop Specific) Recombinant Antibody – Sequence-defined positive control for flow cytometry and target validation. | View SCN9A Products |
| Validator | SCN9A siRNA Set – For specific knockdown verification in cellular assays and specificity controls. | View SCN9A Products |
| Related Target (Safety) | SCN5A (Nav1.5) – Critical cardiac counter-screening target for safety profiling; essential for selectivity assays. | View SCN5A Products |
| Related Target (Synergy) | SCN10A (Nav1.8) – Synergistic nociception pathway for combination pain therapies; TTX-resistant sodium channel. | View SCN10A Products |
| Related Target (Off-Target) | SCN4A (Nav1.4) – Skeletal muscle off-target evaluation for safety profiling. | View SCN4A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-Pass Membrane Conformation | Lentivirus-mediated stable cell line tools ensure native functional folding for Patch-Clamp/Calcium Flux. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Rat/Cynomolgus SCN9A ortholog lentivirus available with Sequence-Verified ORFs. |
| Subfamily Counter Screening (Nav1.5 / Nav1.8 / Nav1.4) | Comprehensive Nav family ORF vectors and Lentivirus for rigorous selectivity profiling; sequence identity cross-checked by NGS. |
| Lack of Reliable Controls | Sequence Verified recombinant benchmark antibodies targeting extracellular loops; validated siRNA for target-specificity confirmation. |
| False Positives in State-Dependent Binding | Endotoxin-controlled (<1 EU/µg) and sequence-verified tools enabling precise functional assay calibration. |
| Cell Line Construction for Electrophysiology | High-titer lentivirus (>10⁸ TU/mL), suitable for Patch-Clamp/FLIPR assays. |
Live SCN9A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
SCN9A encodes the voltage-gated sodium channel Nav1.7, a genetically validated target for non-opioid analgesia. Loss-of-function mutations cause congenital insensitivity to pain, while gain-of-function mutations lead to severe erythromelalgia and paroxysmal extreme pain disorder. Key known mutations include the PERYTHM variant (causing a hyperpolarizing shift of -5.3 mV for the midpoint of activation) and two polymorphisms found in febrile seizure patients (dbSNP:rs121908, uncertain significance). The target also features an IQ domain (UniProt Q15858) implicated in calmodulin binding and channel modulation.
Despite early small-molecule setbacks due to cardiac safety liabilities (Nav1.5 cross-reactivity) and insufficient efficacy, the field is pivoting. Historically dominated by state-dependent small molecule inhibitors, developers are now shifting focus to highly specific monoclonal antibodies, peptide toxins, and gene silencing modalities. First-generation therapies faced clinical hurdles regarding selectivity and blood-nerve barrier penetration; the next wave of R&D targets precise extracellular epitopes and utilizes RNAi/AAV delivery to achieve localized, sustained analgesia without CNS or cardiac toxicity. Dual Nav1.7/Nav1.8 targeting strategies and peripherally restricted agents represent the future frontier of non-opioid pain management.
Functional Domains & Key Mutations
| Feature | Description | Evidence |
|---|---|---|
| IQ Domain | Calmodulin-binding domain involved in calcium-dependent channel regulation. | UniProt Q15858 |
| PERYTHM Mutation | Hyperpolarizing shift of -5.3 mV in activation midpoint; alters channel gating. | UniProt VAR_064595 |
| rs121908 (Febrile Seizures) | Uncertain significance; found in patients with febrile seizures. | UniProt VAR_064596, VAR_064597 |
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (State-Dependent) | Vertex, Biogen, Pfizer, Neurocrine Biosciences, Lilly | Neuropathic Pain, Chronic Pain (Diabetic Neuropathy) | Selectivity Assay (Need Nav1.5/Nav1.8 Lentivirus for cross-reactivity profiling) |
| Peptide / Toxin | Janssen, Amgen, Navega Therapeutics, Scripps Research | Chronic Pain, Refractory Pain (Erythromelalgia) | Functional Patch-Clamp (Need stable Nav1.7 cell lines expressing native conformation) |
| Gene Therapy (RNAi) | Alnylam, Eli Lilly, Sangamo (AAV-ZFP) | Severe Intractable Pain, Diabetic Peripheral Neuropathy | Knockdown Validation (Need High-Purity ORFs and siRNA; stable cell lines for electrophysiology) |
| Monoclonal Antibody | Genentech (Historical), Emerging preclinical programs | Osteoarthritis, Refractory Pain | Binding Specificity (Need native membrane presentation via Lentivirus) |
References & Related Targets
- SCN5A (Nav1.5): Cardiac safety counter-screen; essential for selectivity profiling.
- SCN10A (Nav1.8): Complementary pain target; dual-inhibition strategies.
- SCN4A (Nav1.4): Skeletal muscle off-target evaluation.
全球研发格局与遗传学基础
SCN9A 编码 Nav1.7 电压门控钠通道,是镇痛领域最强遗传学验证的非阿片类靶点。功能缺失突变导致先天性无痛症,功能获得突变引起红斑性肢痛症。已知关键突变包括 PERYTHM (使激活中点超极化偏移 -5.3 mV) 和两种与热性惊厥相关的 SNPs (rs121908, 意义未明)。该通道含有一个 IQ 结构域,参与钙调蛋白结合与通道调控。
市场动态与技术迭代
尽管早期小分子药物因心脏毒性 (Nav1.5 交叉反应) 和疗效不足而受挫,但领域并未沉寂。Vertex 在 Nav1.8 (SCN10A) 上的成功 (VX-548) 重新点燃了资本对钠通道家族的信心。当前研发重点已从传统小分子转向高选择性多肽/毒素 (如蜘蛛毒液衍生肽)、针对特定胞外环的单克隆抗体以及 RNAi/CRISPR 基因疗法。递送技术成为瓶颈,血神经屏障 (BNB) 要求局部靶向递送,例如 AAV 载体或偶联分子定向至背根神经节 (DRG)。
分子差异化与筛选策略
打造 Best-in-class SCN9A 药物的关键在于"绝对选择性"与"功能构象依赖性"。
- 安全性:对 Nav1.5 (心脏)、Nav1.1 (中枢神经) 需 ≥1000 倍选择性窗口,否则致命。
- 亲和力:单抗和多肽必须识别处于特定门控状态 (如失活态) 的三维构象表位,纯化可溶性蛋白丧失构象,导致假阳性。
- 递送:大分子需在 DRG 局部达到有效浓度且无免疫原性。
推荐筛选 Assay
- 自动膜片钳 (APC):评估状态依赖性阻滞。
- 亚家族交叉筛选 Panel:同步构建 Nav1.1-1.9 稳转细胞系,选择性漏斗筛选。
- 钙流/钠流荧光测定 (HTS 级)。
TarMart 解决方案逻辑
SCN9A 是复杂跨膜离子通道,直接销售纯化重组蛋白无法维持正确门控构象。TarMart 主推 SCN9A Lentivirus 和 Promise-ORF,帮助客户在 HEK293/CHO 中快速构建功能完整稳转细胞系,这是高质量 Patch-Clamp 和靶点结合实验的唯一可靠途径。同时提供序列验证的 Benchmark 抗体和 siRNA 校准工具。
关联靶点推荐
- SCN10A (Nav1.8):痛觉传导协同靶点,联合开发必备。
- SCN5A (Nav1.5):心脏安全性反向筛选核心靶点。
- SCN4A (Nav1.4):骨骼肌 off-target 评估。